Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
In a 6-month carcinogenicity study in rasH2 transgenic mice, tirzepatide at doses of 1, 3, and 10 mg/kg administered by subcutaneous injection twice weekly was not tumorigenic
Tirzepatide is typically administered once weekly as a subcutaneous injection, and your provider will guide you on proper injection techniques and dosage adjustments over time to minimize potential side effects
To determine the impact of weight loss on improvements in insulin resistance, multiple linear regression analysis was conducted, taking into account potential confounding variables such as age, sex, metformin use, triglyceride levels, and glycated hemoglobin A1c
Our professional team provides personalized care in a relaxing environment
Keep in mind, that individual experiences may vary with this medical treatment
